(1)
NANJING, China, Feb. 22, 2021 /PRNewswire/ On February 21, 2021, GenScript ProBio and SunRock Biopharma, a company focused on the development of antibody therapeutics targeting cancer, announced a collaboration spanning preclinical discovery to large scale GMP manufacturing for SunRock s CCR9 therapeutic antibody candidates. GenScript ProBio will provide SunRock Biopharma a one-stop-solution from antibody discovery, cell line development, process development to GMP drug substance and drug product manufacturing services.
By leveraging complementary strengths and capabilities, the parties are committed to the R&D, manufacturing process development, NMPA, FDA & EMA IND filings of CCR9 therapeutic antibodies, towards rapid development of novel antibody therapeutics.
CCR9 is a novel therapeutic target expressed in highly aggressive cancer. It is associated with increased metastatic potential and tumor-chemoresistance. This program will enable new treatment formats with innovative
Share this article
Share this article
PISCATAWAY, N.J., Feb. 11, 2021 /PRNewswire/ GenScript USA Inc., the world s leading life science research tools and services provider,
announced today that it has received Emergency Use Authorization by the U.S. Food and Drug Administration s Center for Biologics Evaluation and Research (CBER) for use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in convalescent plasma screening. The cPass kit is the first FDA authorized test that specifically detects COVID-19 neutralizing antibodies without the use of live virus. Neutralizing antibodies block the ability of the virus to infect a cell and are widely recognized biomarkers of immunity.
Share this article
Share this article
PISCATAWAY, N.J., Jan. 13, 2021 /PRNewswire/ GenScript USA Inc., the world s leading research reagent provider, announced today that it has submitted an application to the U.S. Food and Drug Administration s Center for Biologics Evaluation and Research (CBER) for use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in convalescent plasma screening. The kit, which has been authorized by the FDA for emergency use in clinical diagnostics laboratories, is the first commercially available product to specifically detect COVID-19 neutralizing antibodies without the use of live virus. Neutralizing antibodies block the ability of the virus to infect a cell and are widely recognized biomarkers of immunity.
GenScript Granted Authorization for cPass⢠SARS-CoV-2 Neutralization Antibody Detection Test in Brazil
World s first test capable of detecting virus-blocking antibodies that can be performed in standard labs in under an hour
cPass SARS-COV-2 neutralization antibody kit by GenScript Previous Next
Newswise PISCATAWAY, NEW JERSEY, December 14, 2020 – GenScript
USA Inc., the world’s leading research reagent provider, announced today that Brazil s National Health Surveillance Agency (ANVISA) (Agência Nacional de Vigilância Sanitária) has authorized the use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit for detecting neutralizing antibodies. The cPass test is the first and only ANVISA authorized test for detecting neutralizing antibodies to SARS-CoV-2. Neutralizing antibodies specifically block the ability of a virus to infect a cell and are well-recognized to confer immunity.